Author

V. M. Corman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Immunology· 4 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:host-pathogen & immune response· 9 Organism:human· 6 Organism:mouse· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2

Frequent Co-Authors

C. Drosten· 9 shared L. M. Jeworowski· 5 shared M. L. Schmidt· 5 shared D. Niemeyer· 4 shared A. Richter· 3 shared J. Trimpert· 3 shared A. C. Hocke· 2 shared D. J. Smith· 2 shared

Activity by Year

2020-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersImmunology

C. Drosten

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants

B. Mühlemann, J. Trimpert, F. Walper, M. L. Schmidt, S. Schroeder, L. M. Jeworowski, J. Beheim-Schwarzbach, T. Bleicker, D. Niemeyer, J. M. Adler, R. M. Vidal, C. Langner, D. Vladimirova, D. J. Smith, M. Voss, , C. Drosten

The paper uses hamster sera from variant-specific infections to map antigenic differences among SARS-CoV-2 variants, revealing significant antigenic variation among Omicron subvariants.

bioRxiv · Jul 2, 2023Immunology

Repurposing of the antibiotic nitroxoline for the treatment of mpox

D. Bojkova, N. Zoeller, M. Tietgen, K. Steinhorst, M. Bechtel, T. Rothenburger, J. D. Kandler, J. Schneider, V. M. Corman, S. Ciesek, H. F. Rabenau, M. N. Wass, S. Kippenberger, S. Göttig, M. Michaelis, J. Cinatl

This study shows nitroxoline, an antibiotic, inhibits mpox virus replication and remains effective against tecovirimat-resistant strains, suggesting it as a repurposing candidate for mpox treatment.

bioRxiv · Dec 29, 2022Microbiology

Mapping SARS-CoV-2 antigenic relationships and serological responses

S. H. Wilks, B. Muhlemann, X. Shen, S. Tureli, E. B. LeGresley, A. Netzl, M. A. Caniza, J. N. Chacaltana-Huarcaya, V. M. Corman, X. Daniell, M. B. Datto, F. S. Dawood, T. N. Denny, C. Drosten, R. A. M. Fouchier, , D. J. Smith

The paper uses antigenic cartography to analyze cross-reactivity among SARS-CoV-2 variants and human sera, identifying amino acid substitutions and immunodominance patterns affecting immune escape and vaccine efficacy.

bioRxiv · Jan 28, 2022Immunology

Genomic determinants of Furin cleavage in diverse European SARS-related bat coronaviruses

A.-L. Sander, A. Moreira-Soto, S. Yordanov, I. Toplak, A. Balboni, R. S. Ameneiros, V. M. Corman, C. Drosten, J. F. Drexler

The paper identifies molecular determinants of furin cleavage in European SARS-related bat coronaviruses, suggesting conserved mechanisms enabling this feature in the viral reservoir.

bioRxiv · Dec 15, 2021Evolutionary Biology

Post-entry, spike-dependent replication advantage of B.1.1.7 and B.1.617.2 over B.1 SARS-CoV-2 in an ACE2-deficient human lung cell line

D. Niemeyer, S. Schroeder, K. Friedmann, F. Weege, J. Trimpert, A. Richter, S. Stenzel, J. Jansen, J. Emanuel, J. Kazmierski, F. Pott, L. M. Jeworowski, R. Olmer, M.-C. Jaboreck, B. Tenner, , C. Drosten

The paper shows that B.1.1.7 and B.1.617.2 SARS-CoV-2 variants have a replication advantage over B.1 in ACE2-deficient lung cells, suggesting reliance on alternative cellular factors.

bioRxiv · Oct 20, 2021 · PreprintMicrobiology

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies

S. M. Reincke, M. Yuan, H.-C. Kornau, V. M. Corman, S. van Hoof, E. Sanchez-Sendin, M. Ramberger, W. Yu, Y. Hua, H. Tien, M. L. Schmidt, T. Schwarz, L. M. Jeworowski, S. E. Brandl, H. Foverskov Rasmussen, , J. Kreye

SARS-CoV-2 Beta variant infection generates lineage-specific antibodies and cross-reactive antibodies with neutralizing activity against wild-type and other variants.

bioRxiv · Sep 30, 2021Immunology

Enhanced fitness of SARS-CoV-2 variant of concern B.1.1.7, but not B.1.351, in animal models

L. Ulrich, N. J. Halwe, A. Taddeo, N. Ebert, J. Schön, C. Devisme, B. S. Trüeb, B. Hoffmann, M. Wider, M. Bekliz, M. Essaidi-Laziosi, M. L. Schmidt, D. Niemeyer, V. M. Corman, A. Kraft, , C. Benarafa

The paper compares the fitness of SARS-CoV-2 variants B.1.1.7 and B.1.351 in animal models, finding B.1.1.7 has a fitness advantage in ferrets and mice but not in hamsters.

bioRxiv · Jun 28, 2021Microbiology

A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model

J. Kreye, S. M. Reincke, H.-C. Kornau, E. Sanchez-Sendin, V. M. Corman, H. Liu, M. Yuan, N. C. Wu, X. Zhu, C.-C. D. Lee, J. Trimpert, M. Hoeltje, K. Dietert, L. Stoeffler, N. von Wardenburg, , N. Osterrieder

This study identifies a potent SARS-CoV-2 neutralizing antibody that protects hamsters from infection and lung damage.

bioRxiv · Aug 15, 2020Immunology

At least seven distinct rotavirus genotype constellations in bats with evidence of reassortment and zoonotic transmissions

C. Simsek, V. M. Corman, H. U. Everling, A. N. Lukashev, A. Rasche, G. D. Maganga, T. Binger, D. Jansen, L. Beller, W. Deboutte, F. Gloza-Rausch, A. Seebens-Hoyer, S. Yordanov, A. Sylverken, S. K. Oppong, , J. Matthijnssens

The paper identifies seven distinct rotavirus genotype constellations in bats, finds evidence of reassortment, and suggests potential zoonotic transmission to humans and equines.

bioRxiv · Aug 13, 2020Microbiology

Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics

N. C. Gassen, J. Papies, T. Bajaj, F. Dethloff, J. Emanuel, K. Weckmann, D. E. Heinz, N. Heinemann, M. Lennarz, A. Richter, D. Niemeyer, V. M. Corman, P. Giavalisco, C. Drosten, M. A. Muller

This study identifies spermidine, MK-2206, and niclosamide as potential antiviral therapeutics by enhancing autophagy against SARS-CoV-2 in vitro.

bioRxiv · Apr 15, 2020Microbiology